ATE347902T1 - Methode zur verabreichung von peptiden mit insulinotroper wirkung - Google Patents

Methode zur verabreichung von peptiden mit insulinotroper wirkung

Info

Publication number
ATE347902T1
ATE347902T1 AT99306733T AT99306733T ATE347902T1 AT E347902 T1 ATE347902 T1 AT E347902T1 AT 99306733 T AT99306733 T AT 99306733T AT 99306733 T AT99306733 T AT 99306733T AT E347902 T1 ATE347902 T1 AT E347902T1
Authority
AT
Austria
Prior art keywords
peptides
administration
insulinotropic action
insulinotropic
action
Prior art date
Application number
AT99306733T
Other languages
English (en)
Inventor
Benjamin Lee Hughes
Ronald Keith Wolff
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26794577&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE347902(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE347902T1 publication Critical patent/ATE347902T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
AT99306733T 1998-08-28 1999-08-25 Methode zur verabreichung von peptiden mit insulinotroper wirkung ATE347902T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9827398P 1998-08-28 1998-08-28
US10001298P 1998-09-11 1998-09-11

Publications (1)

Publication Number Publication Date
ATE347902T1 true ATE347902T1 (de) 2007-01-15

Family

ID=26794577

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99306733T ATE347902T1 (de) 1998-08-28 1999-08-25 Methode zur verabreichung von peptiden mit insulinotroper wirkung

Country Status (21)

Country Link
EP (1) EP0997151B1 (de)
JP (1) JP2002523466A (de)
KR (1) KR20010073033A (de)
CN (1) CN1314818A (de)
AR (1) AR022368A1 (de)
AT (1) ATE347902T1 (de)
AU (1) AU764371B2 (de)
BR (1) BR9913284A (de)
CA (1) CA2341454A1 (de)
CO (1) CO5090908A1 (de)
CZ (1) CZ2001690A3 (de)
DE (1) DE69934380D1 (de)
EA (1) EA200100289A1 (de)
HR (1) HRP20010141A2 (de)
HU (1) HUP0103369A3 (de)
IL (1) IL141241A0 (de)
NO (1) NO20010982L (de)
PE (1) PE20001031A1 (de)
PL (1) PL346317A1 (de)
TR (1) TR200100600T2 (de)
WO (1) WO2000012116A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
AU2353701A (en) * 2000-01-11 2001-07-24 Novo Nordisk A/S Transepithelial delivery of glp-1 derivatives
US6540983B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
WO2001093837A2 (en) * 2000-06-08 2001-12-13 Eli Lilly And Company Protein powder for pulmonary delivery
NZ523693A (en) * 2000-07-10 2004-08-27 Chiron Corp Macrolide formulations for inhalation and methods of treatment of endobronchial infections
US7144863B2 (en) * 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
MXPA04003553A (es) * 2001-10-18 2004-07-22 Bristol Myers Squibb Co Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas.
ES2500918T3 (es) 2001-12-21 2014-10-01 Human Genome Sciences, Inc. Proteínas de fusión de albúmina e interferón beta
ATE385193T1 (de) 2002-03-20 2008-02-15 Mannkind Corp Inhalationsgerät
EP2409686A1 (de) * 2002-08-01 2012-01-25 Mannkind Corporation Zelltransport-Zusammensetzungen und ihre Verwendungen
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
EP1704165B1 (de) 2003-12-18 2010-03-17 Novo Nordisk A/S Glp-1-verbindungen
AU2005277208B2 (en) 2004-08-20 2011-11-24 Mannkind Corporation Catalysis of diketopiperazine synthesis
DK1791542T3 (en) 2004-08-23 2015-06-15 Mannkind Corp Diketopiperazinsalte for pharmaceutical delivery
KR100704447B1 (ko) * 2005-05-16 2007-04-09 정용현 3단계로 코팅되는 김치 유산균의 코팅방법 및 그로부터 제조된 코팅된 김치유산균 및 코팅된 김치 유산균이 함유된 조성물
BRPI0615819B8 (pt) 2005-09-14 2021-05-25 Mannkind Corp processo para preparar uma composição de distribuição de fármaco compreendendo um agente ativo e uma micropartícula fumaril dicetopiperazina cristalina.
PT1965823T (pt) * 2005-11-04 2016-08-18 Glaxosmithkline Llc Métodos para administração de agentes hipoglicémicos
JP5096363B2 (ja) 2005-12-16 2012-12-12 ネクター セラピューティックス Ｇｌｐ−１のポリマ複合体
CN101389348A (zh) 2006-02-22 2009-03-18 曼金德公司 用于改善包含二酮哌嗪和活性剂的微粒的药物性质的方法
JO2945B1 (en) * 2006-09-13 2016-03-15 سميث كلاين بيتشام كوربوريشن Methods of giving prolonged hypoglycemic agents
EP2152245B1 (de) 2007-04-30 2015-12-02 Novo Nordisk A/S Verfahren zum Trocknen einer Proteinzusammensetzung, getrocknete Proteinzusammensetzung und pharmazeutische Zusammensetzungen mit dem getrockneten Protein
JP2009019027A (ja) * 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
EP2954893A1 (de) * 2007-10-24 2015-12-16 MannKind Corporation Eine inhalierbare, trockenpulver-formulierung, enthaltend glp-1 zur verwendung in der behandlung von hyperglykämie und diabetes
CA3086027C (en) 2008-06-13 2022-05-17 Mannkind Corporation A dry powder inhaler and system for drug delivery
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
MX2010014240A (es) 2008-06-20 2011-03-25 Mankind Corp Un metodo y aparato interactivo para perfilar en tiempo real esfuerzos de inhalacion.
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
DK2379100T3 (en) 2009-01-08 2014-12-01 Mannkind Corp Treatment of hyperglycemia with GLP-1
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
WO2010144789A2 (en) 2009-06-12 2010-12-16 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
WO2011056889A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
KR20130117755A (ko) 2010-06-21 2013-10-28 맨카인드 코포레이션 건조 분말 약물 운반 시스템 및 방법
WO2012135765A2 (en) 2011-04-01 2012-10-04 Mannkind Corporation Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
CN104619369B (zh) 2012-07-12 2018-01-30 曼金德公司 干粉药物输送系统和方法
EP2911690A1 (de) 2012-10-26 2015-09-02 MannKind Corporation Inhalierbare influenza-impfstoffzusammensetzungen und verfahren
WO2014144895A1 (en) 2013-03-15 2014-09-18 Mannkind Corporation Microcrystalline diketopiperazine compositions and methods
JP6491658B2 (ja) 2013-07-18 2019-03-27 マンカインド コーポレイション 熱安定性乾燥粉末医薬組成物及び方法
US11446127B2 (en) 2013-08-05 2022-09-20 Mannkind Corporation Insufflation apparatus and methods
WO2015148905A1 (en) 2014-03-28 2015-10-01 Mannkind Corporation Use of ultrarapid acting insulin
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
US11359267B2 (en) 2017-02-21 2022-06-14 Jfe Steel Corporation High-carbon hot-rolled steel sheet and method for manufacturing the same
GB201917723D0 (en) 2019-12-04 2020-01-15 Nv Rose Llc Stable liquid formulations of glucagon-like peptide 1 or analogues thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5545618A (en) * 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
NZ250844A (en) * 1993-04-07 1996-03-26 Pfizer Treatment of non-insulin dependant diabetes with peptides; composition
US5512549A (en) * 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
CA2468374C (en) * 1996-08-30 2010-12-21 Novo-Nordisk A/S Glp-1 derivatives
UA65549C2 (uk) * 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
KR20010022007A (ko) * 1997-07-18 2001-03-15 추후보정 생물학적 활성 물질의 서방용 생분해성 마크로머

Also Published As

Publication number Publication date
EP0997151A2 (de) 2000-05-03
CA2341454A1 (en) 2000-03-09
WO2000012116A1 (en) 2000-03-09
NO20010982D0 (no) 2001-02-27
HUP0103369A3 (en) 2002-03-28
DE69934380D1 (de) 2007-01-25
HUP0103369A2 (hu) 2002-02-28
CO5090908A1 (es) 2001-10-30
EP0997151B1 (de) 2006-12-13
IL141241A0 (en) 2002-03-10
AR022368A1 (es) 2002-09-04
JP2002523466A (ja) 2002-07-30
BR9913284A (pt) 2001-05-15
AU5584199A (en) 2000-03-21
HRP20010141A2 (en) 2002-02-28
KR20010073033A (ko) 2001-07-31
EA200100289A1 (ru) 2001-10-22
PE20001031A1 (es) 2000-10-12
CN1314818A (zh) 2001-09-26
CZ2001690A3 (cs) 2002-04-17
EP0997151A3 (de) 2000-09-20
PL346317A1 (en) 2002-01-28
AU764371B2 (en) 2003-08-14
NO20010982L (no) 2001-04-27
TR200100600T2 (tr) 2001-07-23

Similar Documents

Publication Publication Date Title
ATE347902T1 (de) Methode zur verabreichung von peptiden mit insulinotroper wirkung
DE69900746D1 (de) Gesteuerte verabreichung von peptiden oder proteinen
DE69831027D1 (de) Vorrichtungen zur Entnahme von weichem Gewebe
DE69903543T2 (de) Formulierungen zur behandlung von magen-speiseröhren reflux
DE69826705D1 (de) Verfahren zur dermalen verabreichung von polypeptiden
ATE235224T1 (de) Implantierbares system mit verzögerter freisetzung von leuprolid
DE69710095D1 (de) Pharmazeutische zubereitung zur behandlung von diabetes
FI970388A (fi) Menetelmä kuvasekvenssien kontrastin parantamiseksi
DE69711034T2 (de) Wässrige fluorpolymerlösungen zur behandlung von harten oberflächen
DE69405201T2 (de) Methode zur Reinigung von Lactid
DE60144083D1 (de) Verfahren zur Herstellung von basischen Aminosäuren
ATE252915T1 (de) Formulierung zur verzögerten freisetzung von peptiden
DE69934939D1 (de) Kompression von Grenzen zwischen Bildern
DE60130008D1 (de) Proteinkombinationen zur heilung von wunden
DK0964856T3 (da) Bicycliske aromatiske aminosyrer
DE69824823D1 (de) Methode zur abgasbehandlung
DE69815167D1 (de) Methode zur Bestimmung von Salz Stöchiometrie
DE60039773D1 (de) Chimäres pflanzenvirus mit peptiden von mucin
DE69943089D1 (de) Methode zur behandlung von staphylokokkeninfektionen
DK0975217T3 (da) Synergistiske blandinger af udvalgte aminosyrer
DE69737067D1 (de) Vakzine zur behandlung von mycosen
DE69534325D1 (de) Peptide zur behandlung von krebs
ATE531724T1 (de) Verfahren zur herstellung von peptiden
DE68906932T2 (de) Verfahren zur reinigung und isolierung carboxyl-endstaendiger peptide.
DE69826393D1 (de) Pökel zur Fleischverarbeitung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties